Key points are not available for this paper at this time.
Despite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice.
Building similarity graph...
Analyzing shared references across papers
Loading...
Vincenzo Di Lauro
Giacomo Barchiesi
Federica Martorana
ESMO Open
University of Naples Federico II
Building similarity graph...
Analyzing shared references across papers
Loading...
Lauro et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d8d9b0d2f7327e70ae46a7 — DOI: https://doi.org/10.1016/j.esmoop.2022.100629